|
1）Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001; 110: 434-7
|
|
|
|
2）Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol. 2014; 18: 770-7
|
|
|
|
|
3）Tomino Y, Endoh M, Nomoto Y, et al. Immunoglobulin A1 and IgA nephropathy. N Engl J Med. 1981; 305: 1159-60
|
|
|
|
|
|
4）Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004; 24: 197-217
|
|
|
|
|
|
5）Novak J, Julian BA, Mestecky J, et al. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol. 2012; 34: 365-82
|
|
|
|
|
|
6）Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014; 124: 2325-32
|
|
|
|
|
|
7）Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001; 59: 1077-85
|
|
|
|
|
|
8）Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001; 60: 969-73
|
|
|
|
|
|
9）Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007; 71: 1148-54
|
|
|
|
|
|
10）Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008; 118: 629-39
|
|
|
|
|
|
11）Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010; 25: 3890-7
|
|
|
|
|
|
12）Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008; 19: 1008-14
|
|
|
|
|
|
13）Horie A, Hiki Y, Odani H, Yasuda Y, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis. 2003; 42: 486-96
|
|
|
|
|
|
14）Inoue T, Sugiyama H, Hiki Y, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010; 136: 447-55
|
|
|
|
|
|
15）He L, Peng Y, Liu H, et al. Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy. Am J Nephrol. 2013; 38: 321-32
|
|
|
|
|
|
16）Chen X, Liu H, Peng Y, et al. Expression and correlation analysis of IL-4, IFN-γ and FcαRI in tonsillar mononuclear cells in patients with IgA nephropathy. Cell Immunol. 2014; 289: 70-5
|
|
|
|
|
|
17）Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014; 289: 5330-9
|
|
|
|
|
|
18）Sato D, Suzuki Y, Kano T, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2012; 27: 1090-7
|
|
|
|
|
|
19）Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014; 9: e89707
|
|
|
|
|
|
20）Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol. 2013; 8: 217-40
|
|
|
|
|
|
21）Matousovic K, Novak J, Yanagihara T, et al. IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant. 2006; 21: 2478-84
|
|
|
|
|
|
22）Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009; 119: 1668-77
|
|
|
|
|
|
23）Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011; 22: 1795-803
|
|
|
|
|
|
24）Okazaki K, Suzuki Y, Otsuji M, et al. Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol. 2012; 23: 1364-74
|
|
|
|
|
|
25）Suzuki H, Suzuki Y, Aizawa M, et al. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int. 2007; 72: 319-27
|
|
|
|
|
|
26）Hashimoto A, Suzuki Y, Suzuki H, et al. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am J Pathol. 2012; 181: 1338-47
|
|
|
|
|
|
27）Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012; 82: 790-6
|
|
|
|
|
|
28）Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011; 6: 1903-11
|
|
|
|
|
|
29）Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012; 23: 1579-87
|
|
|
|
|
|
30）Wada Y, Ogata H, Takeshige Y, et al. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol. 2013; 17: 73-82
|
|
|
|
|
|
31）Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999; 104: 73-81
|
|
|
|
|
|
32）Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014; 9: e98081
|
|
|
|
|